Comparison of fully automated pTau217 plasma assays for Alzheimer’s disease detection

Full poster title: Head-to-head comparison of the fully automated Elecsys pTau217 plasma assay and the Lumipulse pTau217 plasma assay

Blood tests are a non-invasive and cost-effective method for detecting Alzheimer’s disease pathology, including amyloid deposits. Plasma phosphorylated tau 217 (pTau217) is a biomarker with high clinical utility in detecting amyloid pathology. The Elecsys^® Phospho-Tau 217 plasma prototype immunoassay (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) identifies amyloid pathology by quantitatively determining plasma pTau217 levels and has received United States Food and Drug administration Breakthrough Device Designation. The Lumipulse G pTau217 plasma assay is a research use only assay from Fujirebio. In this poster, the authors performed a head-to-head comparison of the Elecsys and Lumipulse pTau217 assays.